Analyst Says Sequencing-Based Dx Could Be 'Ultimate Opportunity' for Illumina

According to investment firm William Blair & Company, Illumina sees its largest diagnostic opportunity in the cancer space, using its MiSeq for targeted sequencing of oncology markers. To support this application, it plans to pursue 510(k) certification for the platform in 2012.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.